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Abstract
Objective—We examine the association of antioxidants and 15-isoprostane F2t with risk of prostate
cancer.
Methods—We conducted a nested case–control study of serum antioxidant biomarkers (selenium,
tocopherols, carotenoids, and retinol) and a urinary oxidation biomarker (15-isoprostane F2t) with
risk of prostate cancer within the Multiethnic Cohort. Demographic, dietary, and other exposure
information was collected by self-administered questionnaire in 1993–1996. We compared
prediagnostic biomarker levels from 467 prostate cancer cases and 936 cancer free controls that were
matched on several variables. Multivariate conditional logistic regression models were used to
compute adjusted odds ratios (ORs) and 95% confidence intervals (CIs).
Results—We observed that there was no overall association of serum concentrations of antioxidants
and urinary concentrations of 15-isoprostane F2t with risk of prostate cancer or risk of advanced
prostate cancer. However, we did observe an inverse association for serum selenium only among
African-American men (p trend = 0.02); men in the third tertile of selenium concentrations had a
41% lower risk (95% CI: 0.38–0.93) of prostate cancer when compared to men in the first tertile.
Conclusions—Overall, our study found no association of serum antioxidants or 15-isoprostane
F2t with the risk of prostate cancer. The observed inverse association of selenium with prostate cancer
in African-Americans needs to be validated in other studies.
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Introduction
Prostate cancer is the leading cancer among males in the US. Over 186,320 new cases were
expected in 2008 [1]. Although it is well established that the risk of prostate cancer changes
with age and differs across ethnicities, evidence for modifiable risk factors such as diet is
limited and inconsistent. Oxidative stress has been linked to carcinogenesis [2] and many
studies have focused on measures of exposure to antioxidants such as selenium, tocopherols,
retinol, and carotenoids (particularly lycopene). The results from studies on antioxidants and
prostate cancer have been inconsistent. A 2004 review of diet and prostate cancer risk illustrates
the variations in results from prospective cohort studies using biomarkers to measure some or
all of the aforementioned antioxidants. Three studies produced inverse effect estimates for one
or more of the antioxidants (<0.80), two studies had effect estimates near 1.0, one study showed
an increase in risk (>1.20), and two studies had effect estimates ranging from 0.50 to 1.08
[3]. Isoprostanes are compounds produced from the peroxidation of arachidonic acid by free
radicals [4]. 15-isoprostane F2t is a biologically active isoprostane known to be a reliable
biomarker of lipid peroxidation [4], but, few epidemiologic studies have examined the
association of circulating 15-isoprostane F2t levels with the risk of cancer.
In this analysis we examined serum biomarkers for antioxidants (selenium, tocopherols, retinol,
lycopene, and other carotenoids), as well as a urine biomarker of oxidation (15-isoprostane
F2t) in a nested case–control study of prostate cancer. Cases and controls were identified
through the prospective Multiethnic Cohort Study of African-Americans, Caucasians,
Japanese-Americans, Latinos, and Native-Hawaiians.
Materials and methods
Study population
Details of the Multiethnic Cohort (MEC) were described previously [5]. In brief, data were
collected between 1993 and 1996 using a 26-page self-administered mail questionnaire sent to
residents of Hawaii and California, mainly Los Angeles County. Subjects were identified
through drivers' license records in both locations; in addition, voter registration records were
used in Hawaii and Health Care Financing Administration files in California. African-
Americans, Caucasians, Japanese-Americans, Latinos, and Native-Hawaiians were the
primary targets for recruitment, but a small number of persons of other ethnicities were also
enrolled in the study. Participation in the cohort was limited to people of ages between 45 and
75 years in 1993, except for Native-Hawaiians who were recruited at 42 years and older. The
MEC dataset consists of 215,251 people, including 96,382 are men. The Institutional Review
Boards of both the University of Hawaii and the University of Southern California approved
the study.
Biospecimen sub-cohort
Participants for this nested case–control study were men from the MEC who had provided
prediagnostic blood specimens primarily between 2001 and 2006 (n = 29,009). Cohort
members were contacted by letter, and then by phone, to request biological specimens (blood
and urine). For those who agreed, a short screening questionnaire (use of anticoagulants, blood
clotting disorders, etc.) and updated information on a few items (including current smoking
habits, weight, vitamin supplement use, colonoscopy/sigmoidoscopy) was administered by
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phone. Specimens were collected at a clinical laboratory or in the subjects' home and were
processed within four hours of collection. Blood samples were drawn in a fasting state for most
cases (83%), and were separated into components (serum, plasma, buffy coat, red cells) under
yellow light and stored in multiple 0.5 cc aliquots in vapor phase of liquid nitrogen freezers.
First morning urines were collected in Los Angeles and overnight samples were collected in
Hawaii. The urine samples were distributed into ten 2 ml aliquots for each subject and stored
in freezers at −80°C.
Selection of cases and controls
Cases of prostate cancer, diagnosed after specimen collection, were identified through linkages
with the Los Angeles County Cancer Surveillance Program, the State of California Cancer
Registry, and the Hawaii Tumor Registry, all members of the Surveillance, Epidemiology, and
End Results program supported by the National Cancer Institute. Advanced prostate cancer
cases were defined as: (1) having either regional or distant spread, and/or (2) having a Gleason
score ≥7 irrespective of tumor stage. A total of 467 prostate cancer cases were identified for
this study. Controls were selected among the male biorepository participants, who were alive
and free of prostate cancer at the age of diagnosis of the case. A control pool that met the
matching criteria was created for each case, from which two controls were randomly selected.
Matching criteria included geographic site (HI, LA), ethnicity, age at specimen collection (±1
year), date (±1 month) and time of day (±2 h) of sample collection, and fasting status (<6, 6–
7, 8–9, 10+ h). Two cases had an extra control matched to ensure availability of an appropriate
urine specimen.
Laboratory analysis
Study samples were analyzed for selenium adjusted for sodium via neutron activation analysis.
This procedure and the associated quality control practices used by this laboratory in
epidemiology studies have recently been described [6]. Each sample was individually placed
in the top-center position of a shuttle rabbit and irradiated for 5 s in the Row I position using
the pneumatic-tube irradiation facility at the University of Missouri-Columbia Research
Reactor (MURR). After a decay of 15 s, each sample was real-time counted for 30 s using a
high-resolution gamma-rays spectrometer. The 161.9 keV gamma-rays from the decay of Se-77
m are used to determine Se concentrations by standard comparison.
Plasma concentrations of tocopherols, retinol, lycopene, and other carotenoids were
determined by high-pressure liquid chromatography with photo diode array detection slightly
modified from our earlier protocol [7] by using 0.3 ml plasma, followed by partitioning into
hexane, drying, and redissolving in 0.15 ml of the HPLC mobile phase. Twenty microliter were
injected onto a Gemini C18 analytical column (150 × 3.2 mm2, 3 μM) coupled to a Gemini
C18 pre-column (4 × 3.0 mm2, 10 μM) (Phenomenex; Torrance, CA) using isocratic elution
with a mobile phase of 665 ml methanol/218 ml dichloromethane/117 ml acetonitrile/2 ml aq.
bis–tris propane (0.5 M pH 6.8) and containing 0.25 g/l BHT at 0.3 ml/min. Carotenoids and
tocopherols (alpha, gamma + beta, and delta-tocopherol) were quantitated by absorbance at
450 and 295 nm, respectively. Beta-tocopherol could not be separated from gamma-tocopherol
in this HPLC system. However, because the contribution of beta-tocopherol to the combined
total is minor, the beta/gamma values in our tables reflect mostly gamma-tocopherol. All urine
samples were measured for 15-isoprostane F2t adjusted for creatinine using a
radioimmunoassay. A solution of radiolabeled tracer (about 833 Bq/ml or 50,000 dpm/Ml in
the RIA buffer) solution was added to tubes containing a mix of the urine sample with bovine-
γ-globulin and RIA buffer and an antibody solution. After incubating overnight and
centrifugating the next day, the radioactivity of the samples were measured by a β-liquid
scintillation counter (Packard TriCarb 2100 TR). Urinary creatinine concentrations were
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measured with a Roche-Cobas MiraPlus chemistry analyzer using a kit from Randox
Laboratories (Crumlin, UK) that is based on a kinetic modification of the Jaffe reaction.
Serum analysis was performed on 461 cases (99%) and 931 controls (99%) for selenium, and
on 382 cases (82%) and 765 controls (82%) with fasting for 8 h or more for tocopherols, retinol,
lycopene, and other carotenoids. Urinalysis for concentration of 15-isoprostane F2t was
performed on 290 cases (62%) and 543 controls (58%) who provided first morning or overnight
urine samples. The remaining respondents (177 cases and 393 controls) did not provide the
requested first morning or overnight urine sample. Therefore, they were asked to provide a
spot urine sample which was inadequate for performing 15-isoprostane F2t urinalysis. The
intra-assay coefficients of variation were 2.3% for serum selenium, 1.5% for serum alpha-
tocopherol, 1.9% for serum gamma-tocopherol, 1.5% for total serum tocopherol, 3.8% for
serum retinol, 2.6% for serum beta-carotene, 2.3% for serum lycopene, 2.0% for beta-
cryptoxanthin, 3.1% for lutein + zeaxanthin, 1.9% for total serum carotenoids, and 10.1% for
urinary 15-isoprostane F2t.
Statistical analysis
We applied multivariate conditional logistic regression models of prostate cancer incidence,
with case–control matched sets as the strata variable, to estimate odds ratios (ORs) and 95%
CIs. We created quartiles for each biomarker variable based on the distribution of cases and
controls combined, and represented them with three indicator variables. Individual trend
variables were created by assigning them the median values of each quartile grouping. We
adjusted for the following covariates in our models: body mass index (≤25, >25 to ≤30, >30
kg/m2), family history of prostate cancer in father and/or brother(s) (yes, no), years of education
(continuous), age at blood draw (continuous), and number of fasting hours prior to blood draw
(continuous). The latter two variables accounted for any systematic differences in these
variables within matched sets. We repeated the analyses using only controls with PSA (prostate
specific antigen) values ≤4.0 ng/ml and their matched cases to minimize any potential bias due
to disease misclassification. We also performed analyses by using only advanced prostate cases
and their matched controls. We examined effect modification in all case–control sets by BMI
and smoking status using a likelihood ratio test comparing a model with interaction terms to a
model with main effects only. We also performed analyses using tertiles of each biomarker for
the three ethnic groups with adequate sample size (African-Americans, Japanese-Americans,
and Latinos). We tested for the interaction of ethnicity with each biomarker using the Wald
test.
Results
Means for body mass index and education were similar for cases and control subjects (Table
1). However, cases had a higher proportion of men with a family history of prostate cancer
than control subjects (12.6% vs. 8.3%, respectively). Median values and interquartile ranges
of the biomarkers were similar for cases and controls. Cases had slightly higher medians for
four analytes—gamma-tocopherol, beta-carotene, total carotenoids, and retinol—while
controls were slightly higher for the rest. The average time from date of specimen collection
to diagnosis for cases was 2 years (data not shown).
We observed no association between serum selenium levels and risk of prostate cancer (Table
2). Although the ORs for serum selenium levels were all below one (OR = 0.82, 95% CI: 0.59–
1.14, for the fourth quartile compared to first quartile), the trend was not monotonic or
statistically significant (p trend = 0.25). We observed no association between serum
concentrations of alpha-tocopherol, gamma-tocopherol, or total tocopherols and risk of
prostate cancer. The odds ratios for the fourth quartile compared to the first quartile of serum
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concentration were 0.95 (95% CI: 0.65–1.41), 0.95 (95% CI: 0.65–1.39), and 1.12 (95% CI:
0.75–1.67) for alpha-tocopherol, gamma-tocopherol, and total tocopherols, respectively.
Serum beta-carotene concentrations were not associated with risk of prostate cancer, though
the ORs were inverse; men in the fourth quartile had an OR = 0.81 (95% CI: 0.55–1.18) when
compared to men in the first quartile. Risk estimates for serum lycopene concentrations
decreased monotonically with increased serum concentrations, but none of the risk estimates
were statistically significant; for the fourth quartile compared to the first quartile, the odds ratio
was 0.78 (95% CI: 0.53–1.14) and there was no statistically significant trend (p = 0.16). We
observed no association between serum beta-cryptoxanthin or serum lutein + zeaxanthin and
risk of prostate cancer. The odds ratios for the fourth quartile compared to the first quartile
were 0.97 (95% CI: 0.66–1.43) and 1.08 (95% CI: 0.73–1.61), respectively. There was also no
association between total serum carotenoids and risk of prostate cancer. For the fourth quartile
compared to the first quartile, the odds ratio was 1.00 (95% CI: 0.67–1.49). Serum retinol was
not associated with the risk of prostate cancer either. The odds ratio for the fourth quartile
compared to the first quartile was 1.05 (95% CI: 0.70–1.58). Finally, urinary 15-isoprostane
F2t levels showed no association with prostate cancer risk; the odds ratio was 0.90 (95% CI:
0.55–1.49) for the fourth quartile compared to first quartile.
Further adjustment by smoking status did not materially change any of the results presented
above (data not shown). When all of the analyses were restricted to control subjects with PSA
values ≤4.0 and their matched cases, our conclusions were unchanged (data not shown). We
also examined effect modification by BMI (<25 and ≥25 kg/m2) and smoking status (never/
ever smoker) and found no statistical evidence for differences across the strata (data not shown).
We repeated the analyses by ethnic groups (Table 3) to see whether the findings in Table 2
appeared consistent. Due to the limited sample size, we were unable to perform analyses on
Native-Hawaiians and Caucasians. The results by ethnic group were most interesting for
selenium. Although the overall analysis in Table 2 indicated a non-statistically significant
decrease in risk of prostate cancer across quartiles of selenium concentrations, the ethnic-
specific analysis was not so consistent. We observed no evidence of an inverse association
between selenium and prostate cancer in Japanese-Americans and Latinos, but there was a
statistically significant inverse association in the African-American men (p trend = 0.02). Men
in the third tertile had a 41% lower risk of prostate cancer when compared to men in the first
tertile (95% CI: 0.38–0.93). However, a test for interaction of selenium and ethnic group was
not statistically significant (p interaction = 0.17).
As in Table 2, the ethnic-specific results for total tocopherols, gamma-tocopherol, and alpha-
tocopherol confirmed the lack of any association with prostate cancer risk. Similar to the overall
results, the ethnic-specific results in Table 3 for beta-carotene serum levels were mostly below
1.0 and not statistically significant. In Table 2, there was a suggestion of a decreasing trend in
risk with increased serum concentrations of lycopene though the trend was not statistically
significant (p trend = 0.16). However, in the ethnic-specific analysis, the results for lycopene
were not consistent, and weakened this observation. The results for beta-cryptoxanthin varied
across ethnic groups, with the Latino men having risk estimates well above 1.0 and the
Japanese-American and African-American men with estimates below 1.0. However, the test
for interaction was not statistically significant (p interaction = 0.48). Similar to the results in
Table 2, the ethnic-specific results for lutein + zeaxanthin showed no association with risk of
prostate cancer. We also observed no associations with retinol or 15-isoprostane F2t and risk
of prostate cancer across ethnic groups.
Table 4 shows results of an analysis restricted to men with advanced prostate cancer and their
matched controls. The lack of association between any of the biomarkers and risk of prostate
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cancer persisted and the risk estimates were generally similar to those for all prostate cancer
cases in Table 2 with the exception of alpha-tocopherol and lutein + zeaxanthin. The risk
estimates for alpha-tocopherol changed direction, but were still not statistically significant. For
lutein + zeaxanthin, the odds ratio for advanced prostate cancer (Table 4) among men in the
fourth quartile compared to the first quartile of serum concentration was double that of all
prostate cancer cases (Table 2); however, both estimates were not statistically significant.
Discussion
In this study, we observed no clear associations between serum levels of selenium, alpha-
tocopherol, gamma-tocopherol, total tocopherols, beta-carotene, lycopene, beta-
cryptoxanthin, lutein + zeaxanthin, total carotenoids, retinol, or urinary 15-isoprostane F2t and
the risk of prostate cancer. We did observe an inverse association for serum selenium, but only
among African-American men. Analyses restricted to men with advanced prostate cancer did
not show any statistically significant associations. The findings were relatively unchanged
when analyses were restricted to controls with normal PSA values and their matched cases.
Thus, our data do not support the role of antioxidants as preventing initiation or progression
of prostate cancer. Our general findings are in concordance with a recent null paper from our
research group that examined dietary and supplemental intake of beta-carotene, lycopene, beta-
cryptoxanthin, lutein, and alpha-tocopherol and prostate cancer incidence in the entire cohort
[8].
Our overall null results on serum selenium agree with two prospective studies [9,10] but differ
from the findings of two others [11,12]. One study found men in the highest quintile of serum
selenium to be protected against prostate cancer when compared to the lowest quintile (OR =
0.38, 95% CI: 0.17–0.85), but no trend with serum concentration was observed [11]. The
Physician's Health Study investigators observed a protective effect against prostate cancer for
the 5th quintile of plasma selenium when cases were limited to those with baseline PSA levels
>4.0 and to those with advanced prostate cancer [12]. However, we could not confirm the
advanced prostate cancer finding in our study. Interestingly, a selenium intervention trial for
skin cancer found selenium supplementation to decrease risk of prostate cancer by 50–65%,
though this was not an a priori hypothesis [13,14].
We did observe a decreased risk of prostate cancer with increasing serum selenium levels
among the African-American men in our study. Although our sample size was limited, we did
run a model with Caucasian men to see if there was any association with selenium and observed
no association with risk of prostate cancer. Interestingly, the African-American men in our
study had the lowest mean selenium levels of all the ethnic groups (0.134 μg/g compared to
0.139 μg/g for Caucasians, 0.149 μg/g for Japanese-Americans, 0.136 μg/g for Latinos, and
0.139 μg/g for Native-Hawaiians). The Physician's Health Study investigators observed a 51%
decreased risk of prostate cancer (95% CI: 0.28–0.86) in their analysis of cases with baseline
PSA >4 ng/ml [12]. Our sample size precluded testing the association further in African-
American men with advanced prostate cancer or with PSA levels >4.0, however, the African-
American men did have the highest PSA levels of all the ethnic groups. The ethnic differences
we observed could also be indicative of ethnic-specific polymorphisms in selenoprotein gene
families, such as glutathione peroxidases. The results of the large ongoing Selenium and
Vitamin E Cancer Prevention Trial (SELECT) of chemoprevention for prostate cancer will be
of particular interest with regard to prostate cancer risk, since it includes African-American
men. Therefore, until we accrue more African-American cases or the SELECT trial publishes
its ethnic-specific results, our finding will need to be interpreted with caution.
We also found that total serum tocopherol, alpha-tocopherol, and gamma-tocopherol were not
associated with risk of prostate cancer, a result reported by several other prospective studies
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[11,15-19] including the European Prospective Investigation into Cancer and Nutrition (EPIC)
[20]. However, baseline serum alpha-tocopherol measurements were inversely associated with
prostate cancer in the Alpha-tocopherol, Beta-carotene Cancer Prevention Study (ATBC)
among smokers in Finland [21]. Men in the highest quintile of serum alpha-tocopherol had a
20% reduction in risk of prostate cancer (95% CI: 0.66–0.96) compared to men in the lowest
quintile. An earlier nested case–control study within the ATBC also observed a decrease in
risk of prostate cancer among men in the highest quintiles of alpha-tocopherol and gamma-
tocopherol, though both were not statistically significant [22]. Two studies reported statistically
significant decrease in the risk of prostate cancer for men in the highest quintile of gamma-
tocopherol compared to the lowest quintile [11,17]. A Swiss study found low levels of
tocopherol to be associated with an increased risk of prostate cancer mortality [23].
We observed no association between serum lycopene and prostate cancer risk, similar to four
other prospective studies [16,17,20,24]. In contrast, the Physician's Health Study observed a
40% reduction in risk of all prostate cancer and a 60% reduction in risk of aggressive prostate
cancer for men in the highest quintile of serum lycopene [19]. However, our advanced prostate
cancer results and those of two other studies [20,24] were not in accordance with these findings.
We observed no association with total carotenoid serum concentrations, beta-carotene, beta-
cryptoxanthin, or lutein + zeaxanthin concentrations, and risk of prostate cancer. Three
prospective studies support our beta-carotene results [16,17,20]. However, a prospective study
in Finland observed an 80% decrease in risk of prostate cancer among men in the highest
quintile of serum beta-carotene [25] while a prospective study in the US found high serum
beta-carotene to increase risk of prostate cancer [24]. Several studies support our null findings
for beta-cryptoxanthin, and lutein + zeaxanthin [17,19,20,24].
Serum retinol levels were not associated with risk of prostate cancer in our study, a finding
supported by several other studies [9,16,17,20,23,25]. In contrast, the Physician's Health Study
observed a 56% increased risk of prostate cancer (95% CI: 1.07–2.27) for men in the fifth
quintile compared to the first quintile of retinol concentration.
A unique aspect of this prospective study was the examination of urinary 15-isoprostane F2t
levels in association with prostate cancer risk. Studies of the oxidation and prostate cancer
using sera have found greater levels of lipid peroxidation in prostate cancer cases when
compared to controls and men with benign prostatic hyperplasia [26,27]. A recent study of
breast cancer and urinary 15-isoprostane F2t levels observed a statistically significant positive
trend in risk of breast cancer with increasing 15-isoprostane F2t levels [28]. Additional studies
of prostate cancer and 15-isoprostane F2t levels will be needed in the future to determine its
value as a biomarker of risk.
Inconsistencies in the results of studies of circulating antioxidants with the risk of prostate
cancer are difficult to reconcile. Population differences in diet and metabolism that might
influence serum or urinary antioxidant concentrations is one possible source of variation
between studies. However, median antioxidant values across studies were reasonably
comparable. For example, the median lycopene values for cases and controls in our study (383.9
and 399.3 ng/ml for all cases and controls and 461.3 and 418.1 ng/ml for Caucasian cases and
controls, respectively) was similar to values in three [16,17,19] of four prospective studies.
Only one study [24] had lycopene values that were much higher than the other studies and they
observed no association with risk of prostate cancer. Likewise, for beta-carotene, the Finnish
study that found it to decrease risk of prostate cancer [25] had mean (no medians reported)
beta-carotene values similar to [17] or lower than [16] studies—including ours—that found no
association. Furthermore, the prospective study which found high beta-carotene levels to
increase risk of prostate cancer [24] had median beta-carotene levels lower than our study, but
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higher than the Finnish study [25]. Perhaps part of the reason for the inconsistencies is due to
differences in time from blood draw to case ascertainment across studies, variations in
laboratory methods, or uncontrolled confounding.
Our study had several strengths. It is a prospective study and specimens were collected before
prostate cancer diagnosis. We were able to examine the consistency of risk estimates for three
ethnic groups, African-Americans, Latinos, and Japanese-Americans. Other prospective
studies consisted mainly of Caucasian men. A limitation of our study was the lack of power in
the analysis of advanced prostate cancer and the analysis by ethnic groups. With the advent of
regular PSA screening, most cases of prostate cancer are being diagnosed early, so that
assembling large numbers of advanced cases is becoming increasingly difficult. However, in
the future, as more cases accrue in large cohorts, these types of analyses will need to be re-
examined.
Overall, our study found no association of selenium, tocopherols, lycopene, other carotenoids,
or 15-isoprostane F2t with the risk of prostate cancer. The observed inverse association of
selenium with prostate cancer in African-Americans is intriguing, but needs to be validated in
other studies, as do our null findings for 15-isoprostane F2t.
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Table 1
Characteristics of cases and controls
Cases Controls
Covariates n = 467 n = 936
Body mass index (kg/m2), mean (SD) 26.2 (4.0) 26.5 (4.1)
Age at blood draw (years), mean (SD) 68.9 (7.1) 68.7 (7.1)
Fasting hours prior to blood draw, mean (SD) 11.8 (4.8) 11.9 (4.9)
High school education or less (%) 34.0 34.4
Family history of prostate cancer (%) 12.6 8.3
Ethnicity (%)
African-American 46.9 46.8
Caucasian 13.1 13.1
Japanese-American 18.8 18.8
Latino 17.8 17.7
Native-Hawaiian 3.4 3.5
Analytes median (interquartile range)
Selenium (μg/g) 0.13 (0.12–0.15) 0.14 (0.13–0.15)
Alpha-tocopherol (mg/dl) 1.41 (1.06–1.97) 1.42 (1.07–1.93)
Gamma-tocopherol (mg/dl) 0.17 (0.09–0.26) 0.16 (0.09–0.26)
Total tocopherols (mg/dl) 1.65 (1.33–2.18) 1.66 (1.33–2.11)
Beta-carotene (μg/dl) 24.3 (13.6–40.9) 23.7 (14.1–40.1)
Lycopene (μg/dl) 38.4 (27.5–52.7) 39.9 (28.9–54.3)
Beta-cryptoxanthin (μg/dl) 20.8 (14.1–31.8) 21.0 (13.4–32.6)
Lutein + zeaxanthin (μg/dl) 40.8 (32.8–53.2) 41.2 (32.3–52.4)
Total carotenoids (μg/dl) 158.9 (121.5–210.2) 157.5 (120.5–205.4)
Retinol (μg/dl) 117.6 (97.0–141.8) 115.1 (96.0–140.3)
15-isoprostane F2t (ng/mg) 3.25 (2.54–4.54) 3.37 (2.71–4.41)
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